(1-benzyloxy-2-oxo-1,8-naphthyridin-4-yl) trifluoromethanesulfonate | 1003933-02-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: (1-benzyloxy-2-oxo-1,8-naphthyridin-4-yl) trifluoromethanesulfonate
• 英文别名: 1-(Benzyloxy)-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl trifluoromethanesulfonate；(2-oxo-1-phenylmethoxy-1,8-naphthyridin-4-yl) trifluoromethanesulfonate
• CAS: 1003933-02-5
• 化学式: C₁₆H₁₁F₃N₂O₅S
• 分子量: 400.335
• InChiKey: XEGWHARRMADNGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  94.2
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  (1-benzyloxy-2-oxo-1,8-naphthyridin-4-yl) trifluoromethanesulfonate 在 palladium dihydroxide 氢气 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0~140.0 ℃ 、101.33 kPa 条件下， 反应 1.33h， 生成 4-[benzyl(methyl)amino]-1-hydroxy-1,8-naphthyridin-2(1H)-one
  参考文献：
  名称：

  WO2008/10964

  摘要：

  公开号：
• 作为产物：
  描述：

  ethyl 1-(benzyloxy)-4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxylate 在 甲醇 、 sodium hydroxide 、 水 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 (1-benzyloxy-2-oxo-1,8-naphthyridin-4-yl) trifluoromethanesulfonate
  参考文献：
  名称：

  WO2008/10964

  摘要：

  公开号：

文献信息

• Endonuclease Activity Inhibition of the NS1 Protein of Parvovirus B19 as a Novel Target for Antiviral Drug Development
  作者：Peng Xu、Safder S. Ganaie、Xiaomei Wang、Zekun Wang、Steve Kleiboeker、Nancy C. Horton、Richard F. Heier、Marvin J. Meyers、John E. Tavis、Jianming Qiu

  DOI：10.1128/aac.01879-18

  日期：2019.3

  Human parvovirus B19 (B19V), a member of the genus Erythroparvovirus of the family Parvoviridae , is a small nonenveloped virus that has a single-stranded DNA (ssDNA) genome of 5.6 kb with two inverted terminal repeats (ITRs). B19V infection often results in severe hematological disorders and fetal death in humans.

  人类副病毒 B19 (B19V)，属于 病毒科 科 病毒科 是一种小型非包膜病毒，其单链 DNA（ssDNA）基因组为 5.6 kb，有两个倒置末端重复序列（ITR）。B19V 感染通常会导致严重的血液病和胎儿死亡。
• [EN] INHIBITORS OF NUCLEOTIDYLTRANSFERASE SUPERFAMILY ENZYMES AS ANTIBIOTICS<br/>[FR] INHIBITEURS D'ENZYMES DE LA SUPERFAMILLE DES NUCLÉOTIDYLTRANSFÉRASES À TITRE D'ANTIBIOTIQUES
  申请人：UNIV SAINT LOUIS

  公开号：WO2018213378A1

  公开（公告）日：2018-11-22

  In one aspect, the present disclosure provides methods of treating a bacterial infection using an inhibitor of the nucleotidyltransferase superfamily enzyme. In some embodiments, the compounds have one of the following formulas (I), (II), (III), or (IV) wherein R1, R2, and R3 are as defined herein or a pharmaceutically acceptable salt thereof. The compounds may be used to treat a bacterial infection including an infection of Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species.

  在某个方面，本公开提供了使用核苷酸转移酶超家族酶抑制剂治疗细菌感染的方法。在某些实施例中，化合物具有以下公式之一（I），（II），（III）或（IV），其中R1，R2和R3如本文所定义或其药学上可接受的盐。这些化合物可用于治疗包括肠球菌，金黄色葡萄球菌，肺炎克雷伯菌，鲍曼不动杆菌，铜绿假单胞菌和肠杆菌属的细菌感染。
• 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS
  申请人：Williams Peter D.

  公开号：US20100056516A1

  公开（公告）日：2010-03-04

  1-Hydroxy naphthyridine compounds (e.g., 1-hydroxy naphthyridin-2(1H)-one compounds of Formula I are inhibitors of HIV integrase and/or HIV RNase H and inhibitors of HIV replication: (I) wherein X and R1-R6 are as defined herein. The compounds are useful in the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other anti-HIV agents such as HIV antivirals, immunomodulators, antibiotics and vaccines.

  1-羟基萘啶化合物（例如，式I中的1-羟基萘啶-2（1H）-酮化合物）是HIV整合酶和/或HIV RNase H的抑制剂，也是HIV复制的抑制剂：（I）其中X和R1-R6如此定义。这些化合物对于预防和治疗HIV感染以及预防、延迟发病和治疗艾滋病非常有用。这些化合物可作为化合物本身或作为药学上可接受的盐的形式用于对抗HIV感染和艾滋病。这些化合物及其盐可作为制药组合物的成分，可以选择与其他抗HIV剂（例如HIV抗病毒药物，免疫调节剂，抗生素和疫苗）组合使用。
• Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold
  作者：Peter D. Williams、Donnette D. Staas、Shankar Venkatraman、H. Marie Loughran、Rowena D. Ruzek、Theresa M. Booth、Terry A. Lyle、John S. Wai、Joseph P. Vacca、Bradley P. Feuston、Linda T. Ecto、Jessica A. Flynn、Daniel J. DiStefano、Daria J. Hazuda、Carolyn M. Bahnck、Amy L. Himmelberger、Geetha Dornadula、Renee C. Hrin、Kara A. Stillmock、Marc V. Witmer、Michael D. Miller、Jay A. Grobler

  DOI：10.1016/j.bmcl.2010.08.135

  日期：2010.11

  Optimization studies using an HIV RNase H active site inhibitor containing a 1-hydroxy-1,8-naphthyridin-2(1H)-one core identified 4-position substituents that provided several potent and selective inhibitors. The best compound was potent and selective in biochemical assays (IC(50) = 0.045 mu M, HIV RT RNase H; 13 mu M, HIV RT-polymerase; 24 mu M, HIV integrase) and showed antiviral efficacy in a single-cycle viral replication assay in P4-2 cells (IC(50) = 0.19 mu M) with a modest window with respect to cytotoxicity (CC(50) = 3.3 mu M). (C) 2010 Elsevier Ltd. All rights reserved.
• INHIBITORS OF NUCLEOTIDYLTRANSFERASE SUPERFAMILY ENZYMES AS ANTIBIOTICS
  申请人：Saint Louis University

  公开号：US20200147086A1

  公开（公告）日：2020-05-14

  In one aspect, the present disclosure provides methods of treating a bacterial infection using an inhibitor of the nucleotidyltransferase superfamily enzyme. In some embodiments, the compounds have one of the following formulas (I), (II), (III), or (IV) wherein R 1 , R 2 , and R 3 are as defined herein or a pharmaceutically acceptable salt thereof. The compounds may be used to treat a bacterial infection including an infection of Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacter species.